MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

accept change(s) to the agreed paediatric investigation plan (MHRA-100291-PIP01-21) and to the deferral

MHRA-100291-PIP01-21-M02

Scope of the Application

Active Substance(s)

imetelstat sodium

Condition(s)

Treatment of acute myeloid leukaemia (AML), Treatment of myelodysplastic syndromes (MDS), including juvenile myelomonocytic leukaemia (JMML)

Pharmaceutical Form(s)

Powder for solution for infusion

Route(s) of Administration

INTRAVENOUS

Name / Corporate name of the PIP applicant

Geron Corporation

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Geron Corporation submitted to the licensing authority on 03/03/2025 13:25 GMT an application for a Modification

The procedure started on 10/04/2025 15:47 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan and to the deferral

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-100291-PIP01-21-M02

Of 19/06/2025 07:10 BST

On the adopted decision for imetelstat (MHRA-100291-PIP01-21-M02) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan)

This decision applies to a Modification for imetelstat, Powder for solution for infusion , INTRAVENOUS USE .

This decision is addressed to Geron Corporation, 919 E. Hillsdale Blvd, Suite 250, Foster City, UNITED STATES OF AMERICA, CA 94404

ANNEX I

1. Waiver

1.1 Condition:

Condition 1: Treatment of acute myeloid leukaemia (AML) The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 28 days of age Pharmaceutical form(s): Powder for solution for infusion Route(s) of administration: INTRAVENOUS USE Reason for granting waiver: on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s). Condition 2: Treatment of myelodysplastic syndromes (MDS), including juvenile myelomonocytic leukaemia (JMML) The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 28 days of age Pharmaceutical form(s): Powder for solution for infusion Route(s) of administration: INTRAVENOUS USE Reason for granting waiver: on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2. Paediatric Investigation Plan:

2.1 Condition(s):

Condition 1: Treatment of acute myeloid leukaemia (AML) Condition 2: Treatment of myelodysplastic syndromes (MDS), including juvenile myelomonocytic leukaemia (JMML)

2.2 Indication(s) targeted by the PIP:

For both conditions: Treatment of paediatric patients with relapsed or refractory AML or MDS, including JMML

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

For both conditions: The paediatric population from birth to less than 28 days of age

2.4 Pharmaceutical Form(s):

For both conditions: Powder for solution for infusion

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	1	Same study for both conditions: Study 1 Development of an age-appropriate presentation of a powder for solution for infusion.
Non-Clinical Studies	2	Studies for condition 1 only : Study 2 Ex-vivo pharmacology study to evaluate the anti-leukaemic activity of imetelstat. Study 3 In-vivo pharmacology study to evaluate the anti-leukaemic activity of imetelstat.
Clinical Studies	3	Same studies for both conditions: Study 4 Open-label, single arm trial to evaluate dose, safety, pharmacokinetics, pharmacodynamics of imetelstat in combination with fludarabine and cytarabine (FLA) chemotherapy in children from 1 year to less than 18 years of age with relapsed or refractory AML, including MDS or JMML. Study 5 (Added during MHRA-100291-PIP01-21-M02) Open-label, randomised controlled trial to evaluate safety,

		pharmacokinetics (PK) and activity of imetelstat in combination with fludarabine and cytarabine (FLA) chemotherapy against FLA chemotherapy in children from 28 days to less than 18 years of age with AML after first relapse or refractory to first line therapy, including MDS or JMML. Study 7 Open-label, randomised controlled trial to evaluate safety, pharmacokinetics (PK) and efficacy of imetelstat in combination with fludarabine and cytarabine (FLA) chemotherapy against FLA chemotherapy in children from 28 days to less than 18 years of age with AML after first relapse or refractory to first line therapy, including MDS or JMML.
Extrapolation, Modeling & Simulation Studies	1	Same study for both conditions: Study 6 Modelling and simulation study to support dose finding of imetelstat as monotherapy in children from 28 days to less than 18 years of age with relapsed or refractory AML or MDS, including JMML.
Other Studies	0	Not applicable.
Other Measures	0	Not applicable.

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	31/10/2035
Deferral of one or more studies contained in the paediatric investigation plan:	Yes